LLY241101C1070000
- 0.48
- 0.000.00%
Eli Lilly and Co Newsroom
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,015
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $994
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $970 to $1,146
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,100
Eli Lilly Is Maintained at Buy by B of A Securities
Eli Lilly Analyst Ratings
Jefferies Adjusts Price Target on Eli Lilly to $994 From $1,113, Maintains Buy Rating
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly Analyst Ratings
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $990
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $990 to $1,050
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025